echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Dr. Wang Haining: Looking forward to conducting more research on thyroid diseases through the platform of the "Tyroid Special Committee"

    Dr. Wang Haining: Looking forward to conducting more research on thyroid diseases through the platform of the "Tyroid Special Committee"

    • Last Update: 2021-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Yimaitong interview report, please do not reprint without authorization
    .

    In order to standardize the diagnosis and treatment process, improve the diagnosis and treatment of thyroid diseases, and promote the development of multidisciplinary cooperation in the field of thyroid diseases, the "Beijing" is sponsored by the Thyroid Professional Committee of the Beijing Society of Endocrinology and Metabolism and undertaken by the Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences and the Third Medical Center of the PLA General Hospital.
    The Inaugural Meeting of the Thyroid Professional Committee of the Society of Endocrinology and Metabolism and Symposium on Hot Thyroid Issues and Cases" was held on July 4, 2021 in the form of a combination of online and offline in the Inner Mongolia Building, Beijing! After the meeting, Yimaitong was honored to invite Dr.
    Wang Haining, a member of the Thyroid Professional Committee of the Beijing Society of Endocrinology and Metabolism and the Department of Endocrinology, Peking University Third Hospital, for an interview
    .

    Dr.
    Wang Haining accepts an exclusive interview with Yimaitong Dr.
    Wang Haining is the chief physician of the Department of Endocrinology, Peking University Third Hospital; Doctor of Medicine, Peking University School of Medicine in 2006; Visiting scholar at the University of Helsinki in 2012; Visiting scholar at the Steno Center in 2015; Hosting the National Natural Science Foundation of China Project; presided over and participated in many national and medical association funds; member of the Diabetes Branch of the Chinese Medical Association; member and secretary of the Beijing Diabetes Association; member of the pituitary group and thyroid group of the Chinese Medical Association Endocrinology Branch; member of the Diabetes Branch of the Society of Women Physicians; Correspondence editorial board member of Chinese Journal of Diabetes; Correspondence editorial board member of Chinese Journal of Endocrinology and Metabolism
    .

    Yimaitong: Hello, Mr.
    Wang.
    You have done a lot of research on the impact of autoimmune thyroid disease on the outcome.
    What new research is planned in this field in the future, and what new work do you hope to develop through the learning? Dr.
    Wang Haining: I am very honored to be a member of the Thyroid Professional Committee of the Beijing Society of Endocrinology and Metabolism.
    I hope to actively promote the diagnosis and treatment of thyroid diseases in Beijing
    .

    Under the leadership of Professor Hong Tianpei from the Endocrinology Department of Peking University Third Hospital and Professor Qiao Jie from the Reproductive Center, we conducted a large-scale RCT study in the field of thyroid autoimmunity and pregnancy outcome.
    For women with positive thyroid function and normal infertility, the intervention of levothyroxine could not reduce the abortion rate, nor did it increase the live birth rate
    .

    This study provides evidence-based evidence for the peri-pregnancy management of infertility groups with positive antibodies, normal thyroid function, and reproductive anxiety
    .

    This is our main original intention of doing this work, and the results of the study are included in the 2021 European Thyroid Association Guidelines for the Diagnosis and Treatment of Assisted Reproductive Women in the Peri-pregnancy Period
    .

    At present, most guidelines still recommend active treatment for women with positive antibodies and TSH 2.
    5~4.
    0mIU/L during pregnancy, although the level of evidence is not high
    .

    However, combining our research results and the Tablet research results published in the New England Journal of Medicine in 2020, the 2021 European Thyroid Society's guidelines for the screening and management of thyroid diseases before assisted reproduction treatment for infertile women have been proposed for the first time.
    These women should be taken Individualized diagnosis and treatment measures: ➤For TSH>2.
    5 IU/L and thyroid antibody-positive women, whether to intervene before ovulation induction is recommended to adopt an individualized treatment plan
    .

    Levothyroxine treatment is based on the results of thyroid function after ovulation induction and embryo transfer; ➤For women with positive thyroid antibodies and TSH>4.
    0 IU/L, levothyroxine therapy is recommended; ➤for negative antibodies, TSH is 2.
    5~normal For women with the upper limit, it is not recommended to give levothyroxine treatment before ovulation induction, and it is recommended to check thyroid function after conception
    .

    Our research work has played a role in promoting the individualized diagnosis and treatment of this type of patients, and the optimization of the management of thyroid diseases during pregnancy is far from over
    .

    The study of thyroid autoimmunity on perinatal outcomes has just explored the two pregnancy outcomes of miscarriage and live birth.
    In the future, thyroid diseases and maternal pregnancy-related complications should be improved, including pregnancy-induced hypertension, gestational diabetes, and offspring development.
    Sexual exploration
    .

     I especially hope to use the platform of the "Tyroid Special Committee" to conduct multi-center research on the basis of our own research, with Beijing as the core area, to do more high-quality research on thyroid diseases and female reproductive health
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.